Combination of estrogens plus antiprogestins with significant partial agonistic effect as an effective treatment of menopausal symptoms and for prevention of the occurrence of breast cancer
Inventors
Nickisch, Klaus • Santhamma, Bindu • Nair, Hareesh • Elger, Walter
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Described herein are compositions and methods for hormone replacement therapy that address the shortcomings of the existing methods. Described herein are pharmaceutically effective partial agonistic antiprogestins. The combined application of estrogens (such as estradiol, estriol and conjugated estrogens) and the disclosed partial agonistic antiprogestins can be used in hormone replacement therapy.
Core Innovation
The disclosed invention concerns hormone replacement therapy that combines an estrogen with a partial agonistic antiprogestin. The partial agonistic antiprogestin is a progesterone receptor partial agonist/antagonist defined by formula (I), including a Het-Aryl group and variable substituents R1, R2, and R3, with at least one of X, Y, and Z not a carbon atom.
The partial agonistic antiprogestin is characterized by activity assessed in a T47D progesterone transactivation assay using R5020 and RU-486 controls, together with EC50 metrics and specified EC50 ratio criteria. The invention also includes characterization concepts using a Guinea pig pure mesoprogestin classification and a McPhail index.
Therapeutic embodiments are described for estrogen combined with the partial agonistic antiprogestin in relation to endometriosis and fibroids. The document further references antiproliferative effects and reduction of breast cancer risk in connection with the described compounds and compositions.
Claims Coverage
The claim coverage centers on a pharmaceutical composition combining an estrogen with a partial agonistic antiprogestin defined by formula (I), with dependent-claim refinements further specifying structural and functional criteria and naming particular antiprogestin candidates.
Pharmaceutical composition with estrogen and partial agonistic antiprogestin formula (I)
A pharmaceutical composition comprising an estrogen and a partial agonistic antiprogestin, wherein the partial agonistic antiprogestin has the formula (I) and at least one of X, Y, and Z is not a carbon atom.
Antiprogestin agonistic and antagonistic EC50 ranges in progesterone transactivation assay
The partial agonistic antiprogestin has an EC50 in a progesterone transactivation assay on human breast cancer (T47D) cells within 1 nM to 10 nM for agonistic activity and within 0.1 nM to 5 nM for antagonistic activity.
EC50 ratio window for agonistic versus antagonistic activity
The partial agonistic antiprogestin has a ratio of EC50 values (agonistic to antagonistic) between 1:0.5 and 1:10 in a progesterone transactivation assay on human breast cancer (T47D) cells.
Pure mesoprogestin classification in Guinea pig model
The partial agonistic antiprogestin is classified as a pure mesoprogestin in the Guinea pig model.
McPhail index characterization above a dose threshold
The partial agonistic antiprogestin shows a McPhail index greater than 2 at doses greater than 1 mg/day.
Selection of antiprogestin candidates by code
The partial agonistic antiprogestin is selected from EC 312, EC 313, EC 317, EC 336, or mixtures thereof.
The claim set requires a pharmaceutical composition with an estrogen plus a partial agonistic antiprogestin defined by formula (I) where at least one of X, Y, and Z is not carbon. Dependent claims then narrow the partial agonistic antiprogestin by specifying quantitative agonistic and antagonistic EC50 criteria in a T47D progesterone transactivation assay, adding a pure mesoprogestin classification in a Guinea pig model, adding a McPhail index threshold at specified dosing, and optionally selecting particular antiprogestin candidates identified as EC 312, EC 313, EC 317, or EC 336, including mixtures.
Stated Advantages
Reduction of breast cancer risk is referenced in connection with the described compounds and compositions.
Antiproliferative effect on breast cancer cells is referenced.
Documented Applications
Hormone replacement therapy combining estrogen with the described partial agonistic antiprogestin is described.
Therapeutic embodiment for endometriosis is described.
Therapeutic embodiment for fibroids is described.
Interested in licensing this patent?